作者
Bernadet T Santema, Wouter Ouwerkerk, Jasper Tromp, Iziah E Sama, Alice Ravera, Vera Regitz-Zagrosek, Hans Hillege, Nilesh J Samani, Faiez Zannad, Kenneth Dickstein, Chim C Lang, John G Cleland, Jozine M Ter Maaten, Marco Metra, Stefan D Anker, Pim van der Harst, Leong L Ng, Peter van der Meer, Dirk J van Veldhuisen, Sven Meyer, Carolyn SP Lam, Arthur Mark Richards, Inder Anand, Chung-Lieh Hung, Lieng Hsi Ling, Houng Bang Liew, Calambur Narasimhan, Tachapong Ngarmukos, Sang Weon Park, Eugenio Reyes, Bambang Budi Siswanto, Wataru Shimizu, Shu Zhang, Adriaan A Voors
发表日期
2019/10/5
期刊
The Lancet
卷号
394
期号
10205
页码范围
1254-1263
出版商
Elsevier
简介
Background
Guideline-recommended doses of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and β blockers are similar for men and women with heart failure with reduced ejection fraction (HFrEF), even though there are known sex differences in pharmacokinetics of these drugs. We hypothesised that there might be sex differences in the optimal dose of ACE inhibitors or ARBs and β blockers in patients with HFrEF.
Methods
We did a post-hoc analysis of BIOSTAT-CHF, a prospective study in 11 European countries of patients with heart failure in whom initiation and up-titration of ACE inhibitors or ARBs and β blockers was encouraged by protocol. We included only patients with left ventricular ejection fraction less than 40%, and excluded those who died within the first 3 months. Primary outcome was a composite of time to all-cause mortality or hospitalisation for heart failure …
学术搜索中的文章
BT Santema, W Ouwerkerk, J Tromp, IE Sama… - The Lancet, 2019